Advancis Pharmaceutical Corporation is a pharmaceutical company focused on developing and commercializing pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing a portfolio of drugs based on novel biological finding that bacteria exposed to antibiotics in front-loaded, sequential bursts or pulses are killed more efficiently and effectively than those exposed to standard antibiotic treatment regimens. Based on this finding, it has developed a once-a-day pulsatile delivery technology, PULSYS. In July 2004, the Company acquired the United States rights to the Keflex brand of cephalexin from Eli Lilly and Company. Under the terms of the agreement, Advancis acquired the exclusive rights to manufacture, market and sell Keflex (cephalexin capsules, USP) in the United States.